Pruszyński M - Search Results

1

Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy.

Gawęda W, Pruszyński M, Cędrowska E, Rodak M, Majkowska-Pilip A, Gaweł D, Bruchertseifer F, Morgenstern A, Bilewicz A. Gawęda W, et al. Among authors: pruszynski m. Nanomaterials (Basel). 2020 Oct 20;10(10):2067. doi: 10.3390/nano10102067. Nanomaterials (Basel). 2020. PMID: 33092037 Free PMC article.

2

Trastuzumab-Modified Gold Nanoparticles Labeled with ²¹¹At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer.

Dziawer Ł, Majkowska-Pilip A, Gaweł D, Godlewska M, Pruszyński M, Jastrzębski J, Wąs B, Bilewicz A. Dziawer Ł, et al. Among authors: pruszynski m. Nanomaterials (Basel). 2019 Apr 18;9(4):632. doi: 10.3390/nano9040632. Nanomaterials (Basel). 2019. PMID: 31003512 Free PMC article.

3

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with ²²⁵Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer.

Cędrowska E, Pruszyński M, Gawęda W, Żuk M, Krysiński P, Bruchertseifer F, Morgenstern A, Karageorgou MA, Bouziotis P, Bilewicz A. Cędrowska E, et al. Among authors: pruszynski m. Molecules. 2020 Feb 25;25(5):1025. doi: 10.3390/molecules25051025. Molecules. 2020. PMID: 32106568 Free PMC article.

4

Evaluation of an Anti-HER2 Nanobody Labeled with ²²⁵Ac for Targeted α-Particle Therapy of Cancer.

Pruszynski M, D'Huyvetter M, Bruchertseifer F, Morgenstern A, Lahoutte T. Pruszynski M, et al. Mol Pharm. 2018 Apr 2;15(4):1457-1466. doi: 10.1021/acs.molpharmaceut.7b00985. Epub 2018 Mar 7. Mol Pharm. 2018. PMID: 29502411

5

Design and Evaluation of ²²³Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy-Part I.

Czerwińska M, Fracasso G, Pruszyński M, Bilewicz A, Kruszewski M, Majkowska-Pilip A, Lankoff A. Czerwińska M, et al. Among authors: pruszynski m. Materials (Basel). 2020 Sep 2;13(17):3875. doi: 10.3390/ma13173875. Materials (Basel). 2020. PMID: 32887308 Free PMC article.

6

Functionalized TiO₂ nanoparticles labelled with ²²⁵Ac for targeted alpha radionuclide therapy.

Cędrowska E, Pruszynski M, Majkowska-Pilip A, Męczyńska-Wielgosz S, Bruchertseifer F, Morgenstern A, Bilewicz A. Cędrowska E, et al. Among authors: pruszynski m. J Nanopart Res. 2018;20(3):83. doi: 10.1007/s11051-018-4181-y. Epub 2018 Mar 20. J Nanopart Res. 2018. PMID: 29576738 Free PMC article.

7

Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.

Rodak M, Dekempeneer Y, Wojewódzka M, Caveliers V, Covens P, Miller BW, Sevenois MB, Bruchertseifer F, Morgenstern A, Lahoutte T, D'Huyvetter M, Pruszyński M. Rodak M, et al. Among authors: pruszynski m. Mol Cancer Ther. 2022 Dec 2;21(12):1835-1845. doi: 10.1158/1535-7163.MCT-21-1021. Mol Cancer Ther. 2022. PMID: 36129807 Free PMC article.

8

Radiochemical separation of ²²⁴Ra from ²³²U and ²²⁸Th sources for ²²⁴Ra/²¹²Pb/²¹²Bi generator.

Pruszyński M, Walczak R, Rodak M, Bruchertseifer F, Morgenstern A, Bilewicz A. Pruszyński M, et al. Appl Radiat Isot. 2021 Jun;172:109655. doi: 10.1016/j.apradiso.2021.109655. Epub 2021 Feb 25. Appl Radiat Isot. 2021. PMID: 33657491

9

²¹¹At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatment.

Lyczko M, Pruszynski M, Majkowska-Pilip A, Lyczko K, Was B, Meczynska-Wielgosz S, Kruszewski M, Szkliniarz K, Jastrzebski J, Stolarz A, Bilewicz A. Lyczko M, et al. Among authors: pruszynski m. Nucl Med Biol. 2017 Oct;53:1-8. doi: 10.1016/j.nucmedbio.2017.05.008. Epub 2017 May 25. Nucl Med Biol. 2017. PMID: 28683361

10

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.

Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Among authors: pruszynski m. Mol Cancer Ther. 2022 Jan;21(1):159-169. doi: 10.1158/1535-7163.MCT-21-0220. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667109 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page